Neuropeptide YY1 receptor polymorphism as a prognostic predictor in Japanese patients with IgA nephropathy

Clinical Nephrology

Volumn 51, Issue 5, 1999, Pages 272-279

  Ito, H ^a   Morita, T ^a   Suehiro, T ^a   Tahara, K ^a   Ikeda, Y ^a   Nakauchi, Y ^a   Makino, S ^a   Nishiya, K ^a   Hashimoto, K ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Angiotensin 1 converting enzyme; Gene polymorphism; Hypertension; IgA nephropathy; Neuropeptide Y

Indexed keywords

CREATININE; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y RECEPTOR;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN URINE LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; BLOOD; GENETIC POLYMORPHISM; GENETICS; PROTEINURIA;

ADULT; CREATININE; FEMALE; GENOTYPE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROTEINURIA; RECEPTORS, NEUROPEPTIDE Y;

EID: 0032587709     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Allen JM, Raine AEG, Ledingham JGG, Bloom SR 1985 Neuropeptide Y - a novel peptide with vasoconstrictor and natriuretic activity. Clin Sci 68: 373-377
2. Bard JA, Walker MW, Branchet TA, Weinshank RL 1995 Cloning and functional expression a human Y4 subtype receptor for pancreatic polypeptide. J Biol Chem 270: 26762-26765
3. Burg M, Menne J, Ostendorf T, Kliem V, Floege J 1997 Gene-polymorphism of angiotensin-converting enzyme and endothelial nitric oxide synthase in patients with primary glomerulonephritis. Clin Nephrol 48: 205-211
4. D'Amico G 1992 Influence of clinical and histological features on actuarial renal survival in adult patients with IgA nephropathy, membranous nephropathy and membranoproliferative glomerulonephritis. Survey of the recent literature. Am J Kidney Dis 20: 315-323
5. Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R 1992 Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog Neurobiol 38: 125-167
6. Eva C, Keinanen K, Monyer A, Seeburg P, Sprengel R 1990 Molecular cloning of a novel G-protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett 271: 80-84
7. Fogarty DG, Maxwell AP, Doherty CC, Hughes AE, Nevin NC 1994 ACE gene typing. Lancet 343: 851
8. Fuxe K, Aguirre A, Agnati LF, von Euler G, Hedlund P, Covenas R, Zoli M, Bjelke B, Eneroth P 1990 Neuropeptide Y and central cardiovascular regulation. Ann NY Acad Sci 611: 111-132
9. Fukushima T, Katamura S, Saiki T, Osawa G 1997 Relationship between neuropeptide Y Y1 receptor gene polymorphism and IgA nephropathy. J Jpn Soc Intern Med 86: 198 (abstract, in Japanese)
10. Grundemar L, Wahlestedt C, Reis DJ 1991 Long-lasting inhibition of the cardiovascular responses to glutamate and the baroreceptor reflex elicited by neuropeptide Y injected into the nucleus tractus solitarius. Neurosci Lett 122: 135-139
11. Grundemar L, Mörner SEJN, Höestätt ED, Wahlestedt C, Håkanson R 1992 Characterization of vascular neuropeptide Y receptors. Br J Pharmacol 105: 45-50
12. Hackenthal E, Aktories K, Jakobs H, Lang RE 1987 Neuropeptide Y inhibits renin release by a pertussis toxin-sensitive mechanism. Am J Physiol 252: F543-F550
13. Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Rodger RSC, Junor BJR, Briggs JD, Connell JM, Jardine AG 1995 Polymorphism in angiotensin-converting enzyme gene and progression of IgA nephropathy. Lancet 345: 1540
14. Heilig M, Widerlöv E 1990 Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr Scand 82: 95-114
15. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA 1992 Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 89: 5794-5798
16. Herzog H, Baumgartner M, Vivero C, Selbie LA, Auer B, Shine J 1993a Genomic organization, localization and allelic difference in the gene for the human neuropeptide YY1 receptor. J Biol Chem 263: 6703-6707
17. Herzog H, Selbie LA, Zee RYL, Morris BJ, Shine J 1993b Neuropeptide-YY1 receptor gene polymorphism: cross-sectional analysis in essential hypertension and obesity. Biochem Biophysic Res Commun 196: 902-906
18. Kobayashi Y, Tateno S, Hiki Y, Shigematsu H 1983 IgA nephropathy: prognostic significance of proteinuria and histopathological alternations. Nephron 34: 146-153
19. Koyama A, Igarashi M, Kobayashi M, Members and coworkers of the Research Group on Progressive Renal Disease 1997 Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis 29: 526-532
20. Mitch WK, Walser M, Buffington GA, Lemann J 1976 A simple method for estimating progression of chronic renal failure. Lancet II: 1326-1329
21. Pfister A, Waeber B, Nussberger J, Brunner HR 1986 Neuropeptide Y normalizes renin secretion in adrenalectomized rats without changing blood pressure. Life Sci 39: 2161-2167
22. 34) neuropeptide Y selectivity identifies postjunctional-mediated actions of neuropeptide Y in vivo rats and dogs. Eur J Phamacol 193: 15-19
23. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F 1990 An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346
24. Rigat B, Hubert C, Corvol P, Soubrier F 1992 PCR detection of the insertion/deletion polymorphism of the human angiotensin-converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 20: 1433
25. Sakai H, Abe K, Kobayashi Y, Koyama A, Shigematsu H, Harada T, Yoshikawa N, Arakawa M, Itoh H, Osawa G, Sakai O, Dohi K, YamanakaN, Nagasawa T, Kurokawa K Joint Committee of Ministry of Health and Welfare of Japan and Japanese Society of Nephrology 1995 Clinical guidelines of IgA nephropathy. Jpn J Nephrol 57: 417-421
26. Schena FP 1990 A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 89: 209-215
27. Schmidt S, Stier E, Hartung R, Stein G, Bahnisch J, Woodroffe AJ, Clarkson AR, Ponticelli C, Campise M, Mayer G, Ganten D, Ritz E 1995 No association of angiotensin-converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 26: 727-731
28. Turton MD, O'Shea D, Bloom SR 1997 Central effects of neuropeptide Y with emphasis on its role in obesity and diabetest In: Grundemar L, Bloom SR (eds) Neuropeptide Y and drug development. Academic Press, San Diego, pp 15-39
29. Wahlestedt C, Yanaihara N, Hakanson R 1986 Evidence for difference pre- and postjunctional receptors for neuropeptide Y and related peptides. Regul Peptides 13: 107-318
30. Wahlestedt C, Grundemar L, Hakanson R, Heilig M, Shen GH, Zukowska-Grojec Z, Reis DJ 1990 Neuropeptide Y receptor subtypes, Y1 and Y2. Ann NY Acad Sci 611: 726
31. Weinberg DH, Sirinathsinghji DJS, Tan CP, Shiao L-L, Morin N, Rigby MR, Heavens RH, Rapoport DR, Bayne ML, Cascieri MA, Strader CD, Linemeyer DL, MacNeil DJ 1996 Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem 271: 16435-16438
32. Yorioka T, Suehiro T, Yasuoka N, Hashimoto K, Kawada M 1995 Polymorphism of the angiotensin-converting enzyme gene and clinical aspects of IgA nephropathy. Clin Nephrol 44: 80-85
33. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O 1995 Role of deletion polymorphism of the angiotensin-converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96: 2162-2169